

"Express Mail" Label No. EV 566968345 US  
Date of Deposit June 2, 2005

10/537227  
CO6 Rec'd PCT/PTO PATENT 2005  
Attorney Docket No.: 082368-004600US  
Client Reference No.: E1-A0309P-US

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Address" service under 37 CFR 1.10 on the date indicated above and is addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

By: 

Aaron Hokamura

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Kazunobu KIRA et al.

Application No.:

Filed:

Int'l Application No.: PCT/JP03/14502

Int'l Filing Date: December 2, 2003

For: FUSED 1,3-DIHYDRO-  
IMIDAZOLE RING COMPOUNDS

Examiner:

Art Unit:

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of references AC -AI are enclosed. U.S. Patent Publications AA and AB are not enclosed in accordance with the USPTO waiver of the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication pursuant to 1287 OG 163.

References AF and AG were cited in an International Search Report in a corresponding PCT application. A copy of this Search Report is also enclosed.


References AF and AG are not in the English Language. Both References (JP 2000-86663 and JP 2001-151777, respectively) are categorized as "X" documents on the enclosed International Search Report. An English language translation of the abstract is also enclosed for the Examiner's convenience.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

  
Kevin Bastian  
Reg. No. 34,774

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, Eighth Floor  
San Francisco, California 94111-3834  
Tel: 415-576-0200  
Fax: 415-576-0300  
KLB:ath  
60505971 v1

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete if Known</b>	
			Int'l Application Number	PCT/JP03/15402 <b>10/537227</b>
			Int'l Filing Date	December 2, 2003
			First Named Inventor	Kira, Kazunobu
			Art Unit	
Examiner Name				
Sheet <b>1</b>	of <b>2</b>	Attorney Docket Number	082368-004600US	

U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	2004/0082570 A1	04/29/2004	Yoshikawa et al.	
	AB	2004/0116328 A1	06/17/2004	Yoshikawa et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
✓	AC	WO	03/104229	A1	12/18/2003	Eisai Co., Ltd.		<input checked="" type="checkbox"/>
	AD	WO	2004/028524	A1	04/08/2004	Eisai Co., Ltd.		<input checked="" type="checkbox"/>
✓	AE	EP	1 338 595	A2	08/27/2003	Eisai Co., Ltd.		<input type="checkbox"/>
✓	AF	JP	2000-86663 (with English Abstract)	A	03/28/2000	Taisho Pharmaceutical Co., Ltd.		<input type="checkbox"/>
✓	AG	JP	2001-151777 (with English Abstract)	A	06/05/2001	Taisho Pharmaceutical Co., Ltd.		<input type="checkbox"/>

Examiner  
Signature

Date  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.  
60505971 v1

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Int'l Application Number	PCT/JP03/15402
				Int'l Filing Date	December 2, 2003
				First Named Inventor	Kira, Kazunobu
				Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	082368-004600US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AH	KIRA, Kazunobu <i>et al.</i> ; "Development of a novel inhibitor of DPP-IV using a byproduct as the lead compound"; <u>National Meeting &amp; Exposition Program: 228th National Meeting</u> ; August 22-26, 2004; Abstract 262; American Chemical Society; Philadelphia, PA.	
	AI	KIRA, Kazunobu <i>et al.</i> ; "Development of a novel inhibitor of DPP-IV using a byproduct as the lead compound"; <u>Yakku Zasshi: Journal of the Pharmaceutical Society of Japan: The 23rd Medicinal Chemistry Symposium; The 12th Annual Meeting of Division of Medicinal Chemistry (Tsukuba)</u> ; November 24-26, 2004; poster 2P-10; pp. 1-13; The Pharmaceutical Society of Japan, Division of Medicinal Chemistry.	

Examiner  
Signature

Date  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.